BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 18815879)

  • 1. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis.
    Weigelt B; Kreike B; Reis-Filho JS
    Breast Cancer Res Treat; 2009 Sep; 117(2):273-80. PubMed ID: 18815879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.
    Bertucci F; Finetti P; Cervera N; Charafe-Jauffret E; Mamessier E; Adélaïde J; Debono S; Houvenaeghel G; Maraninchi D; Viens P; Charpin C; Jacquemier J; Birnbaum D
    Cancer Res; 2006 May; 66(9):4636-44. PubMed ID: 16651414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pathologic aspects of basal-like breast cancers.
    Fadare O; Tavassoli FA
    Nat Clin Pract Oncol; 2008 Mar; 5(3):149-59. PubMed ID: 18212769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The phenotypic spectrum of basal-like breast cancers: a critical appraisal.
    Fadare O; Tavassoli FA
    Adv Anat Pathol; 2007 Sep; 14(5):358-73. PubMed ID: 17717437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genomic profile of HER2-amplified breast cancers: the influence of ER status.
    Marchiò C; Natrajan R; Shiu KK; Lambros MB; Rodriguez-Pinilla SM; Tan DS; Lord CJ; Hungermann D; Fenwick K; Tamber N; Mackay A; Palacios J; Sapino A; Buerger H; Ashworth A; Reis-Filho JS
    J Pathol; 2008 Dec; 216(4):399-407. PubMed ID: 18810758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study.
    Rodríguez-Pinilla SM; Rodríguez-Gil Y; Moreno-Bueno G; Sarrió D; Martín-Guijarro Mdel C; Hernandez L; Palacios J
    Am J Surg Pathol; 2007 Apr; 31(4):501-8. PubMed ID: 17414096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.
    Schuetz CS; Bonin M; Clare SE; Nieselt K; Sotlar K; Walter M; Fehm T; Solomayer E; Riess O; Wallwiener D; Kurek R; Neubauer HJ
    Cancer Res; 2006 May; 66(10):5278-86. PubMed ID: 16707453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity.
    Vincent-Salomon A; Gruel N; Lucchesi C; MacGrogan G; Dendale R; Sigal-Zafrani B; Longy M; Raynal V; Pierron G; de Mascarel I; Taris C; Stoppa-Lyonnet D; Pierga JY; Salmon R; Sastre-Garau X; Fourquet A; Delattre O; de Cremoux P; Aurias A
    Breast Cancer Res; 2007; 9(2):R24. PubMed ID: 17417968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.
    Hagen AI; Bofin AM; Ytterhus B; Maehle LO; Kjellevold KH; Myhre HO; Møller P; Lønning PE
    Acta Oncol; 2007; 46(2):199-203. PubMed ID: 17453369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas.
    Sitterding SM; Wiseman WR; Schiller CL; Luan C; Chen F; Moyano JV; Watkin WG; Wiley EL; Cryns VL; Diaz LK
    Ann Diagn Pathol; 2008 Feb; 12(1):33-40. PubMed ID: 18164413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.
    Miyoshi Y; Kurosumi M; Kurebayashi J; Matsuura N; Takahashi M; Tokunaga E; Egawa C; Masuda N; Kim SJ; Okishiro M; Yanagisawa T; Ueda S; Taguchi T; Tamaki Y; Noguchi S;
    Cancer Lett; 2008 Jun; 264(1):44-53. PubMed ID: 18280644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features.
    Ishihara A; Tsuda H; Kitagawa K; Yoneda M; Shiraishi T
    Breast Cancer; 2009; 16(3):179-85. PubMed ID: 19466513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic molecular classification of breast cancers based on gene expression profiling].
    Feng YM; Li XQ; Sun BC; Gao XC; Gu L; Niu Y; Hao XS
    Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):900-6. PubMed ID: 17533740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
    González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
    Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
    Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
    PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lineage infidelity and expression of melanocytic markers in human breast cancer.
    Bachmeier BE; Nerlich AG; Mirisola V; Jochum M; Pfeffer U
    Int J Oncol; 2008 Nov; 33(5):1011-5. PubMed ID: 18949364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast.
    Vincent-Salomon A; Lucchesi C; Gruel N; Raynal V; Pierron G; Goudefroye R; Reyal F; Radvanyi F; Salmon R; Thiery JP; Sastre-Garau X; Sigal-Zafrani B; Fourquet A; Delattre O;
    Clin Cancer Res; 2008 Apr; 14(7):1956-65. PubMed ID: 18381933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A SAGE (serial analysis of gene expression) view of breast tumor progression.
    Porter DA; Krop IE; Nasser S; Sgroi D; Kaelin CM; Marks JR; Riggins G; Polyak K
    Cancer Res; 2001 Aug; 61(15):5697-702. PubMed ID: 11479200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.
    Van Laere SJ; Van den Eynden GG; Van der Auwera I; Vandenberghe M; van Dam P; Van Marck EA; van Golen KL; Vermeulen PB; Dirix LY
    Breast Cancer Res Treat; 2006 Feb; 95(3):243-55. PubMed ID: 16261404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.